Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL

被引：0
|
作者：
Shanafelt, Tait D. [1 ]
Lanasa, Mark C. [2 ]
Zent, Clive S. [1 ]
Leis, Jose F. [3 ]
Call, Timothy G. [1 ]
LaPlant, Betsy R.
Tun, Han [4 ]
Bowen, Deborah A. [1 ]
Jelinek, Diane F. [5 ]
Hanson, Curtis A. [6 ]
Kay, Neil [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Mayo Clin Arizona, Div Hematol & Med Oncol, Scottsdale, AZ USA
[4] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Immunol, Rochester, MN USA
[6] Mayo Clin, Div Hematopathol, Dept Lab Med, Rochester, MN USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [1] Ofatumumab-Based Chemoimmunotherapy Is Effective and Well Tolerated in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Shanafelt, Tait
    Lanasa, Mark C.
    Call, Timothy G.
    Beaven, Anne W.
    Leis, Jose F.
    LaPlant, Betsy
    Bowen, Deborah
    Conte, Michael
    Jelinek, Diane F.
    Hanson, Curtis A.
    Kay, Neil E.
    Zent, Clive S.
    CANCER, 2013, 119 (21) : 3788 - 3796
  • [2] Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Wierda, W. G.
    Kipps, T. J.
    Duerig, J.
    Griskevicius, L.
    Stilgenbauer, S.
    Mayer, J.
    Gorczyca, M.
    Andersen, M.
    Nielsen, T.
    Russell, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy
    Jewell, Roxanne C.
    Kipps, Thomas J.
    Duerig, Jan
    Griskevicius, Laimonas
    Stilgenbauer, Stephan
    Smolej, Lukas
    Mayer, Jiri
    Hess, Georg
    Hernandez-Ilizaliturri, Francisco J.
    Padmanabhan-Iyer, Swaminathan
    Fang, Lei
    Goldstein, Nancy
    Gorczyca, Michele
    Gupta, Ira
    Lisby, Steen
    Wierda, William G.
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 348 - 356
  • [4] Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
    Czuczman, Myron S.
    Hess, Georg
    Gadeberg, Ole V.
    Pedersen, Lars M.
    Goldstein, Nancy
    Gupta, Ira
    Jewell, Roxanne C.
    Lin, Thomas S.
    Lisby, Steen
    Strange, Claus
    Windfeld, Kristian
    Viardot, Andreas
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (04) : 438 - 445
  • [5] Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL
    Shanafelt, Tait
    Tun, Han
    Hanson, Curtis
    Zent, Clive S.
    Leis, Jose
    Call, Timothy
    LaPlant, Betsy
    Bowen, Deborah
    Laumann, Kristina
    Jelinek, Diane F.
    Kay, Neil E.
    BLOOD, 2010, 116 (21) : 593 - 593
  • [6] Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013;119:3788-96.
    Shanafelt, T.
    Lanasa, M. C.
    Call, T. G.
    Beaven, A. W.
    Leis, J. F.
    LaPlant, B.
    Bowen, D.
    Conte, M.
    Jelinek, D. F.
    Hanson, C. A.
    Kay, N. E.
    Zent, C. S.
    CANCER, 2014, 120 (06) : 926 - 926
  • [7] CHEMOIMMUNOTHERAPY WITH OFATUMUMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PHASE II INTERNATIONAL TRIAL
    Wierda, G.
    Kipps, T.
    Duerig, J.
    Griskevicius, L.
    Stilgenbauer, S.
    Mayer, J.
    Smolej, L.
    Hess, G.
    Griniute, R.
    Hernandez-Ilizaliturri, F.
    Padmanabhan, S.
    Gorczyca, M.
    Gupta, I.
    Nielsen, T.
    Russell, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 320 - 321
  • [8] Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
    Woyach, J. A.
    Ruppert, A. S.
    Heerema, N. A.
    Zhao, W.
    Booth, A. M.
    Ding, W.
    Bartlett, N. L.
    Brander, D. M.
    Barr, P. M.
    Rogers, K. A.
    Parikh, S. A.
    Coutre, S.
    Hurria, A.
    Brown, J. R.
    Lozanski, G.
    Blachly, J. S.
    Ozer, H. G.
    Major-Elechi, B.
    Fruth, B.
    Nattam, S.
    Larson, R. A.
    Erba, H.
    Litzow, M.
    Owen, C.
    Kuzma, C.
    Abramson, J. S.
    Little, R. F.
    Smith, S. E.
    Stone, R. M.
    Mandrekar, S. J.
    Byrd, J. C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2517 - 2528
  • [9] Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
    Fischer, Kirsten
    Bahlo, Jasmin
    Fink, Anna Maria
    Goede, Valentin
    Herling, Carmen Diana
    Cramer, Paula
    Langerbeins, Petra
    von Tresckow, Julia
    Engelke, Anja
    Maurer, Christian
    Kovacs, Gabor
    Herling, Marco
    Tausch, Eugen
    Kreuzer, Karl-Anton
    Eichhorst, Barbara
    Boettcher, Sebastian
    Seymour, John F.
    Ghia, Paolo
    Marlton, Paula
    Kneba, Michael
    Wendtner, Clemens-Martin
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2016, 127 (02) : 208 - 215
  • [10] Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy
    Kay, Neil E.
    Eckel-Passow, Jeanette E.
    Braggio, Esteban
    VanWier, Scott
    Shanafelt, Tait D.
    Van Dyke, Daniel L.
    Jelinek, Diane F.
    Tschumper, Renee C.
    Kipps, Thomas
    Byrd, John C.
    Fonseca, Rafael
    CANCER GENETICS AND CYTOGENETICS, 2010, 203 (02) : 161 - 168
12345